Loading
Nimorazole is the one hypoxic radiosensitiser in routine use: given with radiotherapy for head and neck cancer in Denmark since the DAHANCA 5 trial improved control, and tested across Europe in patients whose tumours carry a hypoxia gene signature.
Nimorazole was developed as an anti-infective and repurposed as a hypoxic cell radiosensitiser because it is far better tolerated than the earlier nitroimidazoles misonidazole and etanidazole. DAHANCA 5 showed higher locoregional control with nimorazole than placebo during radiotherapy for supraglottic and pharyngeal cancer, and Danish practice has included it ever since; a later analysis found the benefit confined to tumours with a 15-gene hypoxia signature. The EORTC 1219 and DAHANCA 29 trials tested it with accelerated chemoradiation in the wider European population and in hypoxia-selected patients. It has no oncology marketing authorisation outside Denmark and is used under national guidance.
A nitroimidazole that mimics oxygen in hypoxic tumour cells, fixing radiation-induced DNA damage that would otherwise be repaired, so the oxygen-starved cells that normally survive radiotherapy are killed.
1.Nimorazole binds its target with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Nimorazole" OR ABSTRACT:"Nimorazole" OR TITLE:"Naxogin" OR ABSTRACT:"Naxogin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Nimorazole, not a curated reading list.
Shares Tumour hypoxia: imaging and modification and the tag radiation-wave3.
Shares Radiosensitisers, Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares DAHANCA 5, Tumour hypoxia: imaging and modification, Radiosensitisers.
Shares Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Radiosensitisers, Head and neck squamous cell carcinoma and the tag radiation-wave3.
Shares Tumour hypoxia: imaging and modification, Radiosensitisers.